We are a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs.
This icon indicates a link to an external site.
November 19, 2009
Astellas and XenoPort Announce Submission of a New Drug Application in Japan
Requesting PMDA Approval of ASP8825/XP13512 for Restless Legs Syndrome
November 10, 2009
CORRECTING and REPLACING GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
Tuesday, November 03, 2009 4:30 p.m. ET
Q3 2009 XenoPort, Inc. Earnings Conference Call
Tuesday, September 22, 2009 1:40 p.m. ET
XenoPort, Inc. at 2009 B of A/Merrill Smid Cap Conference
Legal Message | Privacy | © 2008. All rights reserved.